deltatrials
Recruiting INTERVENTIONAL NCT07489521

Arthrosamid vs. Steroid for the Management of Knee Osteoarthritis

A Randomised Control Trial of the Use of an Intraarticular Hydrogel Arthrosamid® vs. Steroid for the Non-operative Management of Knee Osteoarthritis

Sponsor: Cappagh National Orthopaedic Hospital

Conditions Intraarticular Injection Osteo Arthritis Knee Osteoarthritis
Interventions Arthrosamid® 2.5% iPAAG injectable implant Steroid Drug
Updated 1 time since 2026 Last updated: Apr 23, 2026 Started: Jan 29, 2026 Primary completion: Sep 1, 2027 Completion: Sep 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Intraarticular Injection and Osteo Arthritis Knee and is currently actively recruiting participants. Cappagh National Orthopaedic Hospital leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

The authors aim is to study the effect of this intra-articular medication by randomising approximately 100 patients to the treatment arm of the study Arthrosamid, and 100 patients to the control arm (which will be the current standard of care currently provided at CNOH: intra-articular steroid and bupivacaine). Patients will be referred from Orthopedic clinics and will be eligible if have symptomatic knee pain and arthritis show on prior imaging. Patients will be given information about the study and given time to choose to be enrolled. They will sign consent forms prior to the study. They will be randomized into 2 groups. Both will get single knee joint injections into 1 knee. Either Arthrosamid or intra-articular steroid and bupivacaine. They will be blinded to what they have gotten. They will be followed up at 3, 6 , 12 and 18 months with MRI imaging and functional assessment to assess which is better.

The authors aim is to study the effect of this intra-articular medication by randomising approximately 100 patients to the treatment arm of the study Arthrosamid, and 100 patients to the control arm (which will be the current standard of care currently provided at CNOH: intra-articular steroid and bupivacaine).

Patients will be referred from Orthopedic clinics and will be eligible if have symptomatic knee pain and arthritis show on prior imaging.

Patients will be given information about the study and given time to choose to be enrolled. They will sign consent forms prior to the study.

They will be randomized into 2 groups. Both will get single knee joint injections into 1 knee. Either Arthrosamid or intra-articular steroid and bupivacaine. They will be blinded to what they have gotten. They will be followed up at 3, 6 , 12 and 18 months with MRI imaging and functional assessment to assess which is better.

Status Flow

May 4, 2026 – present · 57 days · daily APIRecruiting

Change History

1 version recorded
Recruiting [daily]

Eligibility Summary

This study will be a randomised control trial of the use of intra-articular Arthrosamid® a novel intraarticular hydrogel vs. standard of care (steroid and local anaesthetic) for the non-operative management of knee osteoarthritis.

Contact Information

Sponsor contact:
  • Cappagh National Orthopaedic Hospital
  • Contura
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations